Online inquiry

IVTScrip™ mRNA-Anti-TFPI, BAY-1093884(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3746MR)

This product GTTS-WQ3746MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets TFPI gene. The antibody can be applied in Hemophilia B research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens; Humanized
RefSeq NM_001032281.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7035
UniProt ID P10646
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TFPI, BAY-1093884(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ3746MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ14653MR IVTScrip™ mRNA-Anti-DPEP3, SC-003 mAb(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SC-003 mAb
GTTS-WQ9481MR IVTScrip™ mRNA-Anti-C5AR1, IPH-5401(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA IPH-5401
GTTS-WQ7140MR IVTScrip™ mRNA-Anti-CTGF, FG-3019(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA FG-3019
GTTS-WQ11421MR IVTScrip™ mRNA-Anti-F, MEDI-8897(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI-8897
GTTS-WQ9149MR IVTScrip™ mRNA-Anti-EGFR, IMGN-289(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA IMGN-289
GTTS-WQ14927MR IVTScrip™ mRNA-Anti-stx2 A-subunit, Shigamabs®(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ3450MR IVTScrip™ mRNA-Anti-S, AZD8895(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AZD8895
GTTS-WQ13420MR IVTScrip™ mRNA-Anti-ERBB2, PRO132365(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA PRO132365
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW